{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T07:56:03Z","timestamp":1764402963863,"version":"build-2065373602"},"reference-count":30,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004396","name":"Thailand Research Fund","doi-asserted-by":"publisher","award":["MRG5680078"],"award-info":[{"award-number":["MRG5680078"]}],"id":[{"id":"10.13039\/501100004396","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012155","name":"National Vaccine Institute (NVI), Thailand","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012155","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.vaccine.2019.10.084","type":"journal-article","created":{"date-parts":[[2019,11,7]],"date-time":"2019-11-07T09:00:48Z","timestamp":1573117248000},"page":"852-858","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["A live attenuated H5N2 prime- inactivated H5N1 boost vaccination induces influenza virus hemagglutinin stalk specific antibody responses"],"prefix":"10.1016","volume":"38","author":[{"given":"Alita","family":"Kongchanagul","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karnyart","family":"Samnuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ponthip","family":"Wirachwong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Somchaiya","family":"Surichan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilaipan","family":"Puthavathana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Punnee","family":"Pitisuttithum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7536-8964","authenticated-orcid":false,"given":"Kobporn","family":"Boonnak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.10.084_b0005","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.virusres.2013.05.006","article-title":"H5N1 vaccines in humans","volume":"178","author":"Baz","year":"2013","journal-title":"Virus Res"},{"key":"10.1016\/j.vaccine.2019.10.084_b0010","doi-asserted-by":"crossref","first-page":"4728","DOI":"10.1128\/JVI.03509-12","article-title":"H3N2 influenza virus infection induces broadly reactive hemagglutinin stalk antibodies in humans and mice","volume":"87","author":"Margine","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2019.10.084_b0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0025797","article-title":"H3N2 influenza infection elicits more cross-reactive and less clonally expanded anti-hemagglutinin antibodies than influenza vaccination","volume":"6","author":"Moody","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2019.10.084_b0020","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/nature06890","article-title":"Rapid cloning of high-affinity human monoclonal antibodies against influenza virus","volume":"453","author":"Wrammert","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2019.10.084_b0025","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1126\/science.1204839","article-title":"A highly conserved neutralizing epitope on group 2 influenza A viruses","volume":"333","author":"Ekiert","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2019.10.084_b0030","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/nsmb.1566","article-title":"Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses","volume":"16","author":"Sui","year":"2009","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.vaccine.2019.10.084_b0035","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1128\/JVI.03004-13","article-title":"Assessment of influenza virus hemagglutinin stalk-based immunity in ferrets","volume":"88","author":"Krammer","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2019.10.084_b0040","doi-asserted-by":"crossref","first-page":"6179","DOI":"10.1128\/JVI.00469-12","article-title":"A pan-H1 anti-hemagglutinin monoclonal antibody with potent broad-spectrum efficacy in vivo","volume":"86","author":"Tan","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2019.10.084_b0045","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.coviro.2013.07.007","article-title":"Influenza virus hemagglutinin stalk-based antibodies and vaccines","volume":"3","author":"Krammer","year":"2013","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.vaccine.2019.10.084_b0050","doi-asserted-by":"crossref","first-page":"9047","DOI":"10.1073\/pnas.1118979109","article-title":"Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells","volume":"109","author":"Li","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2019.10.084_b0055","doi-asserted-by":"crossref","first-page":"845","DOI":"10.3390\/pathogens3040845","article-title":"Animal models for influenza viruses: implications for universal vaccine development","volume":"3","author":"Margine","year":"2014","journal-title":"Pathogens"},{"key":"10.1016\/j.vaccine.2019.10.084_b0060","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1093\/infdis\/jis652","article-title":"1976 and 2009 H1N1 influenza virus vaccines boost anti-hemagglutinin stalk antibodies in humans","volume":"207","author":"Miller","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.10.084_b0065","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1084\/jem.20101352","article-title":"Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection","volume":"208","author":"Wrammert","year":"2011","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2019.10.084_b0070","doi-asserted-by":"crossref","first-page":"10302","DOI":"10.1128\/JVI.01336-12","article-title":"Hemagglutinin stalk-reactive antibodies are boosted following sequential infection with seasonal and pandemic H1N1 influenza virus in mice","volume":"86","author":"Krammer","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2019.10.084_b0075","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1073\/pnas.1200039109","article-title":"Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses","volume":"109","author":"Pica","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2019.10.084_b0080","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/S1473-3099(17)30240-2","article-title":"Safety and immunogenicity of a live attenuated influenza H5 candidate vaccine strain A\/17\/turkey\/Turkey\/05\/133 H5N2 and its priming effects for potential pre-pandemic use: a randomised, double-blind, placebo-controlled trial","volume":"17","author":"Pitisuttithum","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2019.10.084_b0085","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1093\/infdis\/jiq144","article-title":"Comparison of a live attenuated 2009 H1N1 vaccine with seasonal influenza vaccines against 2009 pandemic H1N1 virus infection in mice and ferrets","volume":"203","author":"Chen","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.10.084_b0090","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.coviro.2016.02.002","article-title":"Novel universal influenza virus vaccine approaches","volume":"17","author":"Krammer","year":"2016","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.vaccine.2019.10.084_b0095","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.chom.2015.10.003","article-title":"The quest for a universal flu vaccine: headless HA 2.0","volume":"18","author":"Krammer","year":"2015","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.vaccine.2019.10.084_b0100","doi-asserted-by":"crossref","first-page":"5774","DOI":"10.1128\/JVI.00137-12","article-title":"Influenza viruses expressing chimeric hemagglutinins: globular head and stalk domains derived from different subtypes","volume":"86","author":"Hai","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2019.10.084_b0105","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.jmii.2014.08.014","article-title":"Recent trends in antibiotic prescriptions for acute respiratory tract infections in pediatric ambulatory care in Taiwan, 2000\u20132009: a nationwide population-based study","volume":"49","author":"Lee","year":"2016","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.vaccine.2019.10.084_b0110","doi-asserted-by":"crossref","first-page":"13260","DOI":"10.1128\/JVI.02133-14","article-title":"Induction of broadly reactive anti-hemagglutinin stalk antibodies by an H5N1 vaccine in humans","volume":"88","author":"Nachbagauer","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2019.10.084_b0115","doi-asserted-by":"crossref","first-page":"5666","DOI":"10.1016\/j.vaccine.2017.08.044","article-title":"Influenza A haemagglutinin specific IgG responses in children and adults after seasonal trivalent live attenuated influenza vaccination","volume":"35","author":"Islam","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.10.084_b0120","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1080\/21645515.2015.1069931","article-title":"Assessment of immune responses to H5N1 inactivated influenza vaccine among individuals previously primed with H5N2 live attenuated influenza vaccine","volume":"11","author":"Rudenko","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2019.10.084_b0125","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1086\/526537","article-title":"Evaluation of the safety and immunogenicity of a booster (third) dose of inactivated subvirion H5N1 influenza vaccine in humans","volume":"197","author":"Zangwill","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.10.084_b0130","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJMoa055778","article-title":"Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine","volume":"354","author":"Treanor","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2019.10.084_b0135","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1093\/infdis\/jiv210","article-title":"High-affinity H7 head and stalk domain-specific antibody responses to an inactivated influenza H7N7 vaccine after priming with live attenuated influenza vaccine","volume":"212","author":"Halliley","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.10.084_b0140","doi-asserted-by":"crossref","first-page":"e01996","DOI":"10.1128\/mBio.01996-15","article-title":"Age dependence and isotype specificity of influenza virus hemagglutinin stalk-reactive antibodies in humans","volume":"7","author":"Nachbagauer","year":"2016","journal-title":"MBio"},{"key":"10.1016\/j.vaccine.2019.10.084_b0145","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nm.3443","article-title":"Broadly neutralizing hemagglutinin stalk-specific antibodies require FcgammaR interactions for protection against influenza virus in vivo","volume":"20","author":"DiLillo","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2019.10.084_b0150","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1126\/science.1171491","article-title":"Antibody recognition of a highly conserved influenza virus epitope","volume":"324","author":"Ekiert","year":"2009","journal-title":"Science"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19314732?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19314732?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:39:11Z","timestamp":1759401551000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19314732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S0264410X19314732"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.10.084","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A live attenuated H5N2 prime- inactivated H5N1 boost vaccination induces influenza virus hemagglutinin stalk specific antibody responses","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.10.084","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}